MedTrace Logo

Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis

NCT05648734 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-12-13

No results posted yet for this study

Summary

In this study we aim to evaluate the radiological and functional changes in post-acute covid-19 pulmonary fibrosis patients in relation to anti-inflammatory and/or antifibrotic drugs prescribed during and after covid-19 pneumonia.

Conditions

Interventions

DRUG

Corticosteroids alone

(≥ 20 mg prednisolone or its equivalent for ≥ 10 days after hospital discharge)

DRUG

Corticosteroids + Colchicine

(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days)

DRUG

Corticosteroids + Pirfenidone

(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)

DRUG

Corticosteroids + Colchicine + Pirfenidone for ≥ 14 days

(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Amina Abdel Maksoud, MD · Mansoura University, Faculty of Medicine

  • Dalia Fahmy, MD · Mansoura University, Faculty of Medicine

  • Aida Yousef, MD · Mansoura University, Faculty of Medicine

  • Mohamed Tohlob, MD · Mansoura University, Faculty of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2022-06-15
Completion
2022-09-15
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05648734 on ClinicalTrials.gov